In the Media

03.07.14

Ocular Surgery News / Aganirsen eye drops demonstrated significant benefits among patients with keratitis


23.06.14

Xconomy San Diego 2014 / Antisense and disruptive technologies for drug discovery…..


18.05.14

Schweiz am Sonntag / Kleinfirma greift…… (DE / ENG)


16.05.14

The Pink Sheet Daily / Gene Signal Novel Corneal Neovascularisation product still on track…..


13-14.05.14

Google Alerts / Gene Signal on Google Alerts


14.05.14

FierceBiotech / PhIII eye drug failure? Not at all, says an optimistic Gene Signal


14.05.14

BioWorld Today / Gene Signal International sees enough in aganirsen phase III data for follow-up trial


13.05.14

Le Temps / Après avoir présenté des résultats positifs dans le traitement du psoriasis….


13.05.14

L’AGEFI / Gene Signal a obtenu des résultats positifs de l’étude phase III…


13.05.14

Reuters / Gene Signal in talks for a partner for eye disease drug


12.05.14

AWP Newswire / Résultats positifs avec gouttes de la molécule Aganirsen


22.04.14

Le Temps / Gene Signal demonstrates Aganirsen efficacy in dermatology


11.04.14

BioWorld Today / Aganirsen reduces the size of Psoriatic lesions....


14.04.13

Neue Zürcher Zeitung am Sonntag (NZZ)Gene Signal – Gut unterwegs….


01.04.13

PME Magazine / Gene Signal lève des fonds


31.03.13

NATURE REVIEWS - DRUG DISCOVERY (VOL 12, MARCH)Antisense approval provides boost to the field


14.03.13

L’AGEFI / La stratégie de niche sur le marché de l’angiogenèse


11.03.13

STARTUPTICKER.CH / Gene Signal announces completion of private funding round


01.03.13

TRANSKRIPTGene Signal


01.02.13

BIOPHARM INSIGHTGene Signal to start two Phase II ophthalmology trials by 4Q13


31.01.13

PHARMA TV / ERIC VIAUD, CEO talks to Pharma TV


29.01.13

LE TEMPS / Gene Signal


28.01.13

BIOTECH FINANCESLevée vitaminée pour Gene Signal


24.01.13

BIOWORLD / Gene Signal Raises New Cash for Its Antisense Drug Trials


20.08.12

GENOME ENGINEERING / Antisense – Making sense at last?


10.05.12

DAILY RX / Eye Drops Successfully Treat AMD


10.05.12

MEDICAL NEWS TODAY / Topical Aganirsen Found To Be Active In Retinal Disease


09.05.12

CONTACTLENSES / New eyedrops "can prevent retinal disease"


01.04.12

BILAN / Menace lausannoise sur un blockbuster de roche et Novartis


27.03.12

LE TEMPS / Gene Signal s'attaque à des maladies ophthalmiques


27.03.12

MY PHARMA / Gene Signal : résultats positifs pour Aganirsen en usage topique sur des modèles de maladies rétiniennes


15.02.12

NEWS MEDICAL / Aganirsen demonstrates significant activity in two models of wet AMD, ischemic retinopathy


06.07.11

ESCRS EUROTIMES / Cornea Neovascularization Treatment


02.07.10

MED PAGE TODAY / Conditioning Cornea Improves Transplants


01.07.10

MD INDIA / Corneal Transplant Success Rate Can be Boosted by New Treatment Approach


01.07.10

PHYSORG.COM / Study finds new key to corneal transplant success


01.04.10

OPHTHALMOLOGY TIMES / Ribonucleotide aids post-graft healing


25.10.09

HEALIO / Antisense oligonucleotide drops may inhibit corneal neovascularization


06.10.09

DAILY MAIL / Your new cornea lasts longer


10.09.09

EYE DOC NEWS / Gene Signal Says GS-101 May Prevent Corneal Transplant Rejection


01.09.09

OPHTHALMOLOGY WEB / Gene Signal GS-101 data shows safe and effective inhibition of ophthalmic blood vessel growth


01.12.08

OPHTHALMOLOGY TIMES EUROPE / Graft rejection therapy enters Phase III